The Atherothrombotic disease in heart and brain team (Team 5, P.G. Steg) focuses on clinical epidemiology of CAD (P. Gabriel Steg) and stroke (P. Amarenco), via the design, conduct and analysis of large-scale observational registries and of randomized clinical trials. The team received French government funding for an integrated research program on innovations in atherothrombosis science (RHU IVASC) which involves ongoing epidemiologic studies and interventional studies to establish the relationship(s) between chronic periodontitis, sleep disordered breathing, and atherothrombosis. The TIA.org registry established the benefit of rapid management of transient ischaemic attacks through specialized centers worldwide, initially and at 5-year follow-up.

Recent trials have studied the impact of lipid lowering interventions after acute coronary syndromes (using alirocumab, a PCSK9 inhibitor, in the ODYSSEY OUTCOMES trial) or after ischaemic stroke in patients with atherothrombosis (comparing two target LDL cholesterol levels, in the TST trial which established the clinical benefit of targeting LDL to <70 mg/dL rather than 100 mg/dL). A large-scale trial, THEMIS (the largest randomized trial in diabetes) established the value of dual antiplatelet therapy with ticagrelor and aspirin in patients with stable CAD and diabetes, particularly if they have a prior history of percutaneous coronary intervention.

The research program will be developed on 3 different and synergistic aspects:

1/ Registry-based randomized clinical trials and novel trial designs

2/ Deep learning and cardiology

3/ Evaluation of novel risk factors for atherothrombosis.